麦科奥特冲刺港交所 核心产品MT1013处于III期临床试验
Zhi Tong Cai Jing·2025-09-29 23:24

Core Viewpoint - Shaanxi Maikeao Technology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with CCB International and China Merchants Securities International as joint sponsors [1][3]. Company Overview - Maikeao is a platform-based biotechnology company focused on accelerating the innovation and development of next-generation bispecific/multispecific peptide drugs, with its core product currently in Phase III clinical trials [3]. - The company was established in 2007 and specializes in metabolic diseases, particularly kidney-related diseases and cardiovascular diseases [3]. Key Products - The core product, MT1013, is a globally pioneering dual-target receptor agonist peptide drug designed to target both CaSR and OGP receptors, primarily developed for treating secondary hyperparathyroidism (SHPT) [3]. - MT1013 has shown potential for expansion into additional indications, including chronic kidney disease-mineral and bone disorder (CKD-MBD) with osteoporosis and non-dialysis SHPT [3]. - The company is also advancing three other clinical-stage candidate products, including XTL6001, which is the first and only GLP-1R/GCGR/MasR triple-target agonist approved for clinical trials in both China and the United States [4]. Clinical Trial Results - Clinical trials for MT1013 have demonstrated significant improvements in iPTH, blood calcium, and phosphorus levels, with rapid and durable effects on lowering iPTH, good safety and tolerability, and notable benefits for cardiovascular health [4]. - The II phase clinical trial results indicate positive effects on improving bone density, prompting the company to actively pursue the expansion of MT1013's indications [4]. Financial Performance - Research and development expenses for the fiscal years ending June 30, 2023, 2024, and the first half of 2025 were approximately RMB 87.01 million, RMB 107.02 million, and RMB 40.43 million, respectively [4][6]. - The company reported losses of approximately RMB 195.4 million, RMB 156.8 million, and RMB 49.9 million for the same periods [4][6].